Literature DB >> 33163519

FIB-4 score and hepatocellular carcinoma risk after hepatitis C virus cure: time to revise surveillance?

Antonio Saviano1,2,3, Simona Tripon1,2, Thomas F Baumert1,2,3,4.   

Abstract

Entities:  

Year:  2020        PMID： 33163519      PMCID： PMC7603928          DOI： 10.21037/hbsn.2020.01.05

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   8.265


× No keyword cloud information.
  14 in total

Review 1.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

2.  AASLD guidelines for the treatment of hepatocellular carcinoma.

Authors:  Julie K Heimbach; Laura M Kulik; Richard S Finn; Claude B Sirlin; Michael M Abecassis; Lewis R Roberts; Andrew X Zhu; M Hassan Murad; Jorge A Marrero
Journal:  Hepatology       Date:  2018-01       Impact factor: 17.425

3.  Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Authors:  Fabrice Carrat; Hélène Fontaine; Céline Dorival; Mélanie Simony; Alpha Diallo; Christophe Hezode; Victor De Ledinghen; Dominique Larrey; Georges Haour; Jean-Pierre Bronowicki; Fabien Zoulim; Tarik Asselah; Patrick Marcellin; Dominique Thabut; Vincent Leroy; Albert Tran; François Habersetzer; Didier Samuel; Dominique Guyader; Olivier Chazouilleres; Philippe Mathurin; Sophie Metivier; Laurent Alric; Ghassan Riachi; Jérôme Gournay; Armand Abergel; Paul Cales; Nathalie Ganne; Véronique Loustaud-Ratti; Louis D'Alteroche; Xavier Causse; Claire Geist; Anne Minello; Isabelle Rosa; Moana Gelu-Simeon; Isabelle Portal; François Raffi; Marc Bourliere; Stanislas Pol
Journal:  Lancet       Date:  2019-02-11       Impact factor: 79.321

Review 4.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2018-04-05       Impact factor: 25.083

5.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

6.  Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.

Authors:  George N Ioannou; Lauren A Beste; Pamela K Green; Amit G Singal; Elliot B Tapper; Akbar K Waljee; Richard K Sterling; Jordan J Feld; David E Kaplan; Tamar H Taddei; Kristin Berry
Journal:  Gastroenterology       Date:  2019-07-26       Impact factor: 22.682

7.  The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.

Authors:  Maki Tobari; Etsuko Hashimoto; Makiko Taniai; Kazuhisa Kodama; Tomomi Kogiso; Katsutoshi Tokushige; Masakazu Yamamoto; Nishino Takayoshi; Katagiri Satoshi; Araida Tatsuo
Journal:  J Gastroenterol Hepatol       Date:  2019-12-03       Impact factor: 4.029

8.  High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers.

Authors:  Beomseok Suh; Sehhoon Park; Dong Wook Shin; Jae Moon Yun; Hyung-Kook Yang; Su Jong Yu; Cheong-Il Shin; Jin-Soo Kim; Eunmi Ahn; Hyejin Lee; Jin Ho Park; BeLong Cho
Journal:  Hepatology       Date:  2015-02-13       Impact factor: 17.425

9.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

10.  Validation of modified fibrosis-4 index for predicting hepatocellular carcinoma in patients with compensated alcoholic liver cirrhosis.

Authors:  Ji Hyun Kim; Minjong Lee; Seung Woo Park; Myungho Kang; Minjeong Kim; Sang Hoon Lee; Tae Suk Kim; Jin Myung Park; Dae Hee Choi
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.